SA Gayther, H Song, SJ Ramus, SK Kjaer, AS Whittemore, L Quaye, J Tyrer, D Shadforth, E Hogdall, C Hogdall, J Blaeker, R DiCioccio, V McGuire, PM Webb, J Beesley, AC Green, DC Whiteman, Australian Ovarian Cancer Study Group, MT Goodman, G Lurie, ME Carney, F Modugno, RB Ness, RP Edwards, KB Moysich, EL Goode, FJ Couch, JM Cunningham, TA Sellers, AH Wu, MC Pike, ES Iversen, JR Marks, M Garcia-Closas, L Brinton, J Lissowska, B Peplonska, DF Easton, I Jacobs, BAJ Ponder, J Schildkraut, CL Pearce, G Chenevix-Trench, A Berchuck, PDP Pharoah, Ovarian Cancer Association Consortium
High-risk susceptibility genes explain <40% of the excess risk of familial ovarian cancer. Therefore, other ovarian cancer susceptibility genes are likely to exist. We have used a single nucleotide polymorphism (SNP)-tagging approach to evaluate common variants in 13 genes involved in cell cycle control-CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, and CDKN2D-and risk of invasive epithelial ovarian cancer. We used a two-stage, multicenter, case-control study. In stage 1, 88 SNPs that tag common variation in these genes were genotyped in three studies from the United Kingdom, United States, and Denmark ( approximately 1,500 cases and 2,500 controls). Genotype frequencies in cases and controls were compared using logistic regression. In stage 2, eight other studies from Australia, Poland, and the United States ( approximately 2,000 cases and approximately 3,200 controls) were genotyped for the five most significant SNPs from stage 1. No SNP was significant in the stage 2 data alone. Using the combined stages 1 and 2 data set, CDKN2A rs3731257 and CDKN1B rs2066827 were associated with disease risk (unadjusted P trend = 0.008 and 0.036, respectively), but these were not significant after adjusting for multiple testing. Carrying the minor allele of these SNPs was found to be associated with reduced risk [OR, 0.91 (0.85-0.98) for rs3731257; and OR, 0.93 (0.87-0.995) for rs2066827]. In conclusion, we have found evidence that a single tagged SNP in both the CDKN2A and CDKN1B genes may be associated with reduced ovarian cancer risk. This study highlights the need for multicenter collaborations for genetic association studies.